Where will drug innovation go in the future? Industry: three directions worth reference

[pharmaceutical network market analysis] in recent years, driven by pharmaceutical policies such as volume purchase, the industry pattern has been constantly changing, a number of pharmaceutical enterprises have been eliminated, and a number of pharmaceutical enterprises have been upgraded and transformed In the long run, innovation will run through the core of the progress of pharmaceutical R & D industry Only by gradually changing from quantity based survival to quality based development and strengthening the layout of innovation can pharmaceutical enterprises stand firm and compete with multinational pharmaceutical enterprises So, where will drug innovation go in the future? The industry believes that, in combination with the development status of domestic innovative drug industry, there are three directions for domestic innovative drug enterprises to be worth layout Direction 1: from fast follow to best in class, or even first in class In other words, pharmaceutical companies should change from fast follow-up to quality and even innovation speed in new drug research and development As we all know, innovative drugs belong to the industry of high risk and high return The industry believes that the time window of innovative drugs fast follow is narrow, and its listing value is large within 5 years However, there is a large market for some diseases When the initial treatment fails, drugs with the same mechanism of action are usually used as substitutes The rapid follow-up varieties in this field are of great value For example, antidepressant (SSRI), autoimmune (TNF - α), wet macular degeneration (Wamd) and so on It is believed that in the next 5-10 years in China, the innovative drugs are mainly fast follow, bio similar drugs and bio innovative drugs, with low risk and high value The key recommended enterprises in the field of Chinese innovative medicine are Hengrui medicine, Fosun medicine, etc In addition, innovative drug companies need to pursue quality and innovation speed in order to be more competitive in the market and seize the dominant position in advance Direction 2: go abroad and expand the international market On December 20, 2019, L-amlodipine maleate (listed in China: Xuanning), an innovative antihypertensive drug independently developed by Shiyao group, was reviewed and approved by the U.S Food and drug administration as a new compound, becoming the first innovative drug approved by the U.S by a local Chinese pharmaceutical enterprise This also means that China's innovative drugs have gone abroad and entered the U.S market, ushering in a historic moment of development The industry believes that with the strong support of the state for drug innovation, innovation has become the common choice of large domestic leading pharmaceutical enterprises In addition to Sinopharm group, it can be predicted that in the future, more Chinese innovative drugs will go abroad and expand the international market This will also help innovative pharmaceutical enterprises improve their competitiveness and brand influence, and gain more market share Direction three, non crowded track layout At present, whether it's generic or innovative drugs, the track is crowded The industry points out that there are too many convergence of drug research and development in China's pharmaceutical industry As for the hot track PD-1 / PD-L1, as of December 2019, 5 products have been approved for listing in China, 3 products have submitted NDA applications, and 7 products are in phase III clinical, which shows that the market competition is fierce and the risk is high Relatively speaking, there is still a certain development space for non crowded track For example, some investors will arrange their investments according to the opportunities provided by the Chinese market, especially the unsatisfied clinical pain points, including some rare diseases In addition, in the field of gene early screening and early diagnosis, this is closely related to the huge market in China and the rigid demand for payment, so some investors will also extend their view to biotechnology Some equipment related to the operation, including mass spectrometry, etc.